Isavuconazole off-label use as an empirical treatment of invasive fungal infections

Abstract

Given its good tolerance and broad-spectrum, isavuconazole is increasingly used off-label as an empirical therapy of invasive fungal infections. We retrospectively reviewed isavuconazole empirical treatment during a 12-month period in four hospitals. During isavuconazole treatment (n=27), none of the patients had a mycological evidence for fungal infection, but 19% (5/27) developed liver test abnormalities without leading to isavuconazole discontinuation. Isavuconazole could be considered as an off-label empirical therapy only if patients cannot receive caspofungin or liposomal amphotericin B.

Keywords: Efficacité mycologique; Empirical therapy; Hepatic safety; Hors AMM; Isavuconazole; Mycological efficacy; Off-label; Tolérance hépatique; Traitement empirique.